Cambridge MedChem Consulting

Cytochrome P450 occupy a central role in drug discovery, drug interactions with these enzymes can be described in three ways, metabolism, inhibition and induction. Since CYP450 metabolism is the major route for elimination of many drugs anything that interferes with that process can have profound effects. CYP450 inhibition can prolong the half-life of the given […]

The latest OpenADMET newsletter is out, highlights include Generated nearly 150,000 measurements across more than 30,000 compounds: the largest publicly available ADMET datasets worldwide, representing a more than 10x increase in publicly available data. Solved 184 co-crystal structures of small molecules bound to PXR, effectively tripling the publicly available data for this target. Run three hi…

New AI sandbox will help make medicines safer, speed up development, and reduce reliance on animal testing. If you are involved in using AI/ML in drug discovery then this initiative could well be of interest. The UK will launch a first-of-its-kind initiative to test how artificial intelligence (AI) can help make medicines safer for patients – as announced […]

The latest update of the ChEMBL database is out. There are now nearly 3 million structures, 2 million assays covering over 18,000 targets. One of the big updates has been the targeted protein degradation. 2,921,148 compounds (of which 2,897,819 have mol files)3,824,604 compound records (non-unique compounds)24,527,044 activities1,970,438 assays18,552 targets101,100 documents Full detail…

As part of my work I’ll be invited to help startups or review spinouts, this is always really interesting to learn about new science or insights from really smart scientists. However, one of the problems is often navigating through unlabelled presentations or disparate folders on different computers containing excel, word, pdfs etc. Simply putting everything […]

Arvinas, Inc. (Nasdaq: ARVN), announced that the U.S. Food and Drug Administration (FDA) has granted approval for VEPPANU (vepdegestrant, ARV-471) for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer. PROTACs are bifunctional molecules that bind to the ta…

The 10th Fragment-based Drug Discovery Meeting is at Churchill College, Cambridge on 📅 Monday 14th September – Wednesday 16th September 2026. Deadline to submit your abstract is Midnight BST, Friday 3rd July, 2026 and you can submit them here.https://hg3.co.uk/fragments/ The following are the confirmed speakers so far: Dan Erlanson, FrontierAndrea Gohlke, AstraZenecaChristian Kersten, J…

This meeting will be held at Burlington House, London, UK on Wednesday 8th April 2026. A one-day conference on Chemical Structure Representations will bring together researchers from academia, industry, and software development to explore how we encode, interpret, and leverage molecular structures in modern chemical science. From classical line notations and connection tables to graph […]

The New Approaches to the Treatment of Parkinson’s disease was a great success. Many thanks to everyone who attended, I’ve written a brief report of the meeting here.